“[Out] of everything going on, this is probably 1 of the most exciting areas in prostate cancer,” says Jason M. Hafron, MD.
In this video, Jason M. Hafron, MD, shares why he thinks PSMA is “disruptive technology” in prostate cancer. Hafron is a partner at the Michigan Institute of Urology, PC; an associate professor of urology at the William Beaumont School of Medicine, Oakland University; and the director of robotic surgery at Beaumont Hospital Royal Oak in Michigan. He was speaking at the 2021 LUGPA annual meeting.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.